Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world pharmacokinetics of immune checkpoint inhibitors (ELICIT)
2021-001509-66Phase 4Terminated
- Sponsor
- Radboud University Medical Center
- Start
- Jul 2021
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab, atezolizumab, durvalumab, ipilimumab and nivolumab in cancer (5 arms), sponsored by Radboud University Medical Center. Primary endpoint: Pharmacokinetic characteristics of immune checkpoint inhibitors. Started Jul 2021; status: terminated.
02
Drugs
03
Conditions
cancer
Beyond the preview
Go deeper on 2021-001509-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001509-66.